Hep Voice September - December 2024

Welcome to Hep Voice!

As we close out the year, I find myself reflecting on the remarkable efforts of our global hepatitis community. This has been a year of intensified advocacy, with a renewed sense of urgency driving action. From the World Hepatitis Day theme, “It’s Time for Action” to the World Hepatitis Summit’s call to “Integrate, Accelerate, and Eliminate”, these messages resonate even more strongly as we approach the pivotal moment of reviewing progress towards the WHO 2030 elimination goals in 2025. 

Ending the year with the first-ever World Hepatitis Testing Week feels particularly significant. Testing remains a cornerstone in elimination efforts, since most people living with viral hepatitis are still undiagnosed. Without diagnosis, we cannot prevent transmission, provide treatment, and achieve elimination. Turn to page 10 to read about the incredible initiatives across the globe to ramp up testing. 

Looking ahead to 2025, we will deepen our focus on key areas, including liver cancer (see page 8), preventing mother-to-child-transmission, and addressing mental health, stigma, and discrimination (see page 20). Recognising the vital role of advocacy, we aim to further strengthen our CIP Accelerator Programme, empowering the next generation of advocates to drive change. Learn more about its impact so far on page 18.  

As we edge closer to our elimination goal, collaboration has never been more important. Thank you for being part of our journey. Together, we can build a future free from viral hepatitis. 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close